Dual Enkephalinase Inhibitors and Their Role in Chronic Pain Management.

Warren A Southerland, Justin Gillis, Sumanth Kuppalli, Alex Fonseca, Andrew Mendelson, Storm V Horine, Nitin Bansal, Amitabh Gulati

Journal: Current pain and headache reports 2021;25(5):29

PMID: 33761014

Abstract

PURPOSE OF REVIEW

Dual enkephalinase inhibitors (DENKIs) are pain medications that indirectly activate opioid receptors and can be used as an alternative to traditional opioids. Understanding the physiology of enkephalins and their inhibitors and the pharmacology of these drugs will allow for proper clinical application for chronic pain patients in the future.

RECENT FINDINGS

DENKIs can be used as an alternative mode of analgesia for patients suffering from chronic pain by preventing the degradation of endogenous opioid ligands. By inhibiting the two major enkephalin-degrading enzymes (neprilysin and aminopeptidase N), DENKIs can provide analgesia with less adverse effects than nonendogenous opioids. The purpose of this paper is to review the current literature investigating DENKIs and explore their contribution to chronic pain management.

Address: Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA. [email protected].; Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.; Department of Anesthesiology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.; Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.